Learn · regulatory literacy

What is the FDA's 503A bulk substances list?

The 503A Bulk Drug Substances List names the active ingredients a state-licensed pharmacy may use to compound medicine for an individual prescription. If a substance is not FDA-approved and not on this list (or covered by an official monograph), pharmacies have no affirmative federal authorization to compound it. That single membership test is what most peptide legality questions actually turn on.

Published Aug 21, 2026 (ET) · every claim sourced below

Where the list comes from

Section 503A of the Food, Drug, and Cosmetic Act governs traditional compounding: a licensed pharmacist making a drug for a specific patient's prescription. The ingredients allowed are limited to three groups - substances with an applicable official monograph, components of FDA-approved drugs, and substances on the FDA's Bulk Drug Substances List, developed through rulemaking with a public docket (FDA-2015-N-3534).

Getting a substance onto that list is a long road: someone nominates it, the FDA's scientists review it, the Pharmacy Compounding Advisory Committee (PCAC) discusses and votes, and then - only if the FDA chooses to act - the agency runs notice-and-comment rulemaking to amend the list. The July 2026 peptide votes were the committee step of that road, not the end of it.

What being on the list does - and does not - mean

On the list means a state-licensed pharmacy may compound the substance for an individual prescription. It does not mean the substance is an FDA-approved drug, that it is sold over the counter, or that products already on the market containing it are legal. Approval and compounding eligibility are different tracks entirely.

Off the list (and unapproved) means compounding pharmacies have no affirmative federal authorization to make it - which is the current position of every peptide the July 2026 committee recommended, including BPC-157 and TB-500. The recommendation is real forward motion; the list membership has not changed.

Current statuses mentioned here

Asked and answered

Is a substance on the 503A list an FDA-approved drug?
No. The 503A list only governs pharmacy compounding for individual prescriptions. FDA approval is a separate process with its own standards; a compounding-legal substance is still not an approved drug.
Who decides what goes on the 503A list?
The FDA, through notice-and-comment rulemaking. The Pharmacy Compounding Advisory Committee votes first, but its votes are advisory - the agency can follow them, ignore them, or take years to act.
How long does it take to add a substance to the list?
After a favorable committee vote, the FDA must choose to start rulemaking: a proposed rule, a public comment period of roughly 60 to 90 days, then a final rule. The whole process is generally estimated at 12 to 24 months - and the FDA is not obliged to start it.

Sources

Keep going

What does an FDA advisory committee vote actually change?Was BPC-157 banned - or approved? Neither.All learn articlesThe full atlas